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Dengue viruses (DENVs) are mosquito-borne flaviviruses that infect humans. The clinical presentation of
DENV infection ranges from inapparent infection to dengue hemorrhagic fever and dengue shock syndrome.
We analyzed samples from a pediatric dengue cohort study in Sri Lanka to explore whether antibody responses
differentiated clinically apparent infections from clinically inapparent infections. In DENV-naive individuals
exposed to primary DENV infections, we observed no difference in the quantity or quality of acquired antibod-
ies between inapparent and apparent infections. Children who experienced primary infections had broad,
serotype–cross-neutralizing antibody responses that narrowed in breadth to a single serotype over a 12-month
period after infection. In DENV immune children who were experiencing a repeat infection, we observed a
strong association between preexisting neutralizing antibodies and clinical outcome. Notably, children with pre-
existing monospecific neutralizing antibody responses were more likely to develop fever than children with
cross-neutralizing responses. Preexisting DENV neutralizing antibodies are correlated with protection from
dengue disease.
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Dengue virus (DENV) is a positive-stranded RNA virus
that is transmitted to humans via the bite of Aedesmos-
quitoes. DENVs exist as 4 serotypes, DENV1–4, which
circulate in tropical and subtropical regions. Currently,
over two thirds of the world’s population is at risk of
being exposed to DENV [1, 2]. A recent study estimates
that 390 million DENV infections occur globally each
year, rendering DENV the most common mosquito-
borne viral pathogen among humans [3].
Natural human DENV infection can result in clini-
cally inapparent or apparent infections. Apparent infec-
tions, which account for less than half of total DENV
infections, manifest as mild dengue fever, severe dengue
hemorrhagic fever, or potentially fatal dengue shock
syndrome [3]. The most significant risk factor for severe
disease is previous DENV infection: an individual ex-
periencing secondary infection with a heterologous
DENV serotype faces greater risk of developing severe
disease than someone experiencing primary infection
[4–8]. Antibody-dependent enhancement is the leading
explanation for the increased risk of severe dengue dis-
ease following reinfection. The antibody-dependent
enhancement theory postulates that primary DENV
infection induces cross-reactive nonneutralizing anti-
bodies that promote entry of DENV particles into
FcγR-bearing cells upon secondary infection with a
heterologous DENV serotype. This phenomenon is be-
lieved to result in increased cellular viral burden and
subsequent severe disease [9–11].
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Many studies have been performed to examine the role of an-
tibodies in severe dengue disease [10, 12–16]. A topic that has
been less studied is a comparison of the role of antibodies in
clinically inapparent versus clinically apparent DENV infection
[17–19]. In this study, we used sera collected from a prospective
pediatric fever surveillance study in Colombo, Sri Lanka [20], to
test our hypothesis that antibody responses are linked to the de-
velopment of inapparent and apparent DENV infections.
MATERIALS AND METHODS
Human Subjects Protocol Approval
Ethical approval for this research was obtained from the Ethical
Review Committee of the Faculty of Medicine, University of
Colombo, and the Institutional Research Board of the Interna-
tional Vaccine Institute, Seoul, Korea. The University of North
Carolina (UNC) institutional review board determined that its
approval was not required because participating UNC investiga-
tors were not involved in human subjects research. Only
children whose parents or legal guardians provided written in-
formed consent were enrolled in the study.
Cell Lines and Viruses
U937 monocytic cells stably transfected with the gene encoding
DC-SIGN (U937–DC-SIGN cells) were maintained in Roswell
Park Memorial Institute medium supplemented with 5% fetal
bovine serum, 1% L-glutamine, 1% penicillin/streptomycin,
1% nonessential amino acids, and 0.05 mM β-mercaptoethanol.
The C6/36-derived World Health Organization reference
DENV strains DENV1 (West Pac 74), DENV2 (S-16803),
DENV3 (CH 53598), and DENV4 (TVP-376) were used in all
infection-based experiments.
Sample Collection
Surveillance and sample collection methods were previously
detailed [20, 21]. Briefly, between November 2008 and January
2010, blood samples were collected from 799 children aged ≤12
years in Colombo, at enrollment (baseline) and 12 months later
(follow-up). In addition, among children who experienced fe-
brile illness, blood samples were obtained upon fever onset
(acute phase specimens) and ≥10 days following fever dissipa-
tion (convalescent phase specimens) [20]. Blood samples were
stored as dried blood spots (DBS) on protein saver cards (What-
man, United Kingdom; ID Biological Systems, Greenville, SC)
[22, 23] or were centrifuged and stored as plasma.
Elution of Antibodies From DBS
DBS diluent volume was determined on the basis of standard
plasma dilutions in pilot experiments, using matched DBS
and plasma obtained from our dengue traveler cohort [24].
Antibodies were eluted from DBS by submerging filter paper
in diluent appropriate for subsequent assay. DBS/diluent
mixtures were incubated at 37°C for 2 hours. Resulting DBS
eluates (sera) were used in immunoglobulin G (IgG), immuno-
globulin M (IgM), and neutralization assays, as described below.
Detection of DENV-Specific IgG and IgM Antibodies
Immunoassays for detection of DENV-specific IgG and IgM
antibodies were performed as previously described [25, 26].
Sera dilutions of 1:100 and 1:50 were evaluated in IgG and
IgM enzyme-linked immunosorbent assays (ELISAs), respec-
tively. Cutoffs for IgM and IgG positivity were determined on
the basis of positive control samples and, where applicable,
are represented as standard deviations relative to normal
human sera (NHS) controls (n = 10; pooled).
Detection of DENV Neutralizing Antibodies
Sera were assessed for the presence of neutralizing antibodies
against each DENV serotype, using a flow cytometry–based
neutralization assay with U937 DC-SIGN cells, as previously
described [27, 28]. Sera dilutions were 1:40–10 240 in 4-fold in-
crements, unless otherwise noted. Samples were run on GUAVA
easyCyte HT and analyzed on GUAVASoft software (Millipore,
Billerica, MA). Sigmoidal curves were generated using Prism
v4.0 (GraphPad Software, La Jolla, CA). The 50% neutralization
titer (NT50) was calculated as the serum dilution that neutralizes
50% of each DENV serotype. The seroconversion threshold was
set to ≥50% neutralization at a ≥1:40 serum dilution.
Laboratory Confirmation of DENV Infections
To identify clinically apparent DENV infections, acute- and
convalescent-phase samples were collected from children with
fever and tested by polymerase chain reaction and paired IgG
and IgM serologic analysis, as previously described [20]. Details
of how inapparent DENV infections were detected are specified
in the Supplementary Materials. Briefly, all children were
screened for increases in neutralizing antibody levels over the
study year by testing paired baseline and 12-month follow-up
samples (at dilutions of 1:40 and 1:640) by means of a neutral-
ization assay (Supplementary Table 1). Cases were then con-
firmed by a neutralization assay with the full serum dilution
series (Supplementary Figure 1). DENV infections occurring
in children who did not have laboratory-confirmed apparent
dengue fever during the study year were classified as inapparent
DENV infections. Dengue cases were further classified as pri-
mary or secondary on the basis of the affected individual’s base-
line DENV naive or immune status, respectively. Notably, all
DENV cases in this study were confirmed by a gold-standard
neutralization assay [27, 28]. Supplementary Table 2 displays
the sensitivity and specificity of the IgG ELISA to detect
DENV cases, calculated using results of the gold-standard neu-
tralization assay. Although it is possible that some inapparent
infections were missed dengue fever cases, efforts were made
to ascertain case detection by educating parents and having a
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study team visit each house weekly [21]. Loss to follow-up was
minimal: of 800 children enrolled, only 1 child withdrew during
the 12 months [20, 21].
Quantitative Analysis of the Breadth of Neutralizing
Antibody Responses
The ability of a serum specimen to neutralize each DENV sero-
type was calculated as log2[reciprocal NT50 / 10]. The neutrali-
zation breadth of a serum specimen was expressed as the
average difference in titer between the virus best neutralized
by that specimen (the maximum titer) and the titers for each
of the other 3 DENV types. Thus, a value close to 0 indicates
that the serum specimen neutralized all DENV types similarly,
while a higher value indicates that the specimen neutralized one
DENV type better than it neutralized the other 3 types.
Statistical Analyses
To compare DENV IgG levels between inapparent and apparent
groups, we used unpaired Student t tests. Repeated measure
1-way analysis of variance (ANOVA) with the Tukey multiple
comparison post hoc test was used to compare DENV IgG levels
in paired baseline, acute phase, convalescent phase, and follow-
up groups. To compare the breadth of the neutralizing antibody
responses between groups, we performed Fisher exact tests, de-
fining outcome categories as “monotypic” (ie, seroconversion to
1 serotype) and “heterotypic” (ie, seroconversion to ≥2 sero-
types). The Pearson product-moment correlation test was
used to determine the linear relationship between elapsed
time and neutralization breadth. In the quantitative analysis
of neutralization breadth, the Wilcoxon rank sum test was
used for statistical comparison between groups, as samples
were not normally distributed. To analyze the difference in
the mean number of serotypes neutralized at baseline and fol-
low-up for secondary inapparent cases, we used a paired Student
t test. A 1-way ANOVA with a Tukey multiple comparison post
hoc test was used to compare the mean number of serotypes neu-
tralized at baseline, the acute phase, the convalescent phase, and
follow-up for secondary apparent cases. For some assays, sample
variability exists because of the limited quantity of sample avail-
able for the multiple and repeat analysis of the various assays,
rather than because of loss at follow-up. P values were determined
by 2-tailed analyses, unless otherwise specified. Generation of
graphs and statistical analyses was completed using Prism v4.0.
RESULTS
We used blood samples from a prospective pediatric dengue co-
hort study in Colombo to compare antibody responses between
children with clinically inapparent dengue infection and those
with clinically apparent dengue infection. The cohort population,
study design, surveillance methods, and epidemiological find-
ings are detailed elsewhere [20, 21]. As previously reported,
we identified 35 primary infections and 32 secondary and repeat
infections over the 12-month study period (Table 1) [20]. Forty
of the infections (20 primary infections and 20 secondary and
repeat infections) were classified as inapparent because they oc-
curred in children who did not have laboratory-confirmed
dengue fever during the 12-month period of active disease
surveillance.
Antibody Responses Following Primary DENV Infections
First, we characterized antibody responses following primary
DENV exposure. With apparent infections, for which we
knew the date of fever onset, we found a significant negative
correlation between the time that elapsed after infection and
the breadth of neutralization across the 4 serotypes (Pearson
r = −0.69; P < .01): children who experienced dengue fever re-
cently had neutralizing antibody responses against a greater
Table 1. Summary of Confirmed Cases of Dengue Virus (DENV) Infection in a Sri Lankan Pediatric Cohort [20]
Baseline Statusa
DENV Infection, Children, No.
No Infection, Children,
No. (n = 732)f
Primary Infection (n = 35) Secondary Infection (n = 32)
Inapparentb Apparentc Inapparentd Apparente
DENV naive (n = 358) 20 15 NA NA 323
DENV immune (n = 441) NA NA 20 12 409
Abbreviations: IgG, immunoglobulin G; NA, not applicable; RT-PCR, reverse transcription polymerase chain reaction.
a Determined by testing a baseline sample for DENV IgG, using an enzyme-linked immunosorbent assay.
b Determined by detection of DENV IgG seroconversion at follow-up and confirmed by neutralization curves.
c Confirmed by RT-PCR and serologic analyses indicating the presence of DENV during fever and further classified as primary on the basis of baseline DENV IgG–
naive status.
d Determined by a 2-dilution neutralization screen and confirmed by neutralization curves.
e Confirmed by RT-PCR and serologic analyses indicating the presence of DENV during fever and further classified secondary based on baseline DENV IgG immune
status.
f Defined as children who did not acquire DENV infection during the study period.
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number of serotypes than children who experienced dengue fever
early in the study year (Figure 1A). For all primary infections,
both inapparent and apparent, we tested follow-up sera for pres-
ence of DENV IgM, which is indicative of recent infection (ie,
infection within the past 6 months) [29]. Serotype–cross-neutral-
izing sera were more likely than monotypic sera to be IgM pos-
itive (P < .05; Figure 1B), further confirming the association
between recent primary exposure and broad neutralization.
We then compared acquired DENV-specific antibody re-
sponses in children with primary inapparent infection and
those with primary apparent infection. We found no difference
in total levels of DENV-binding IgG (Figure 1C) or the ability
of acquired antibodies to neutralize the 4 DENV serotypes
(Figure 1D). Both primary inapparent and apparent DENV in-
fections induced neutralizing antibody responses that were
monotypic in some cases and heterotypic in other cases. To-
gether, these data indicate that children experiencing primary
inapparent infection and those experiencing apparent infec-
tions develop similar DENV-specific antibody responses.
Furthermore, primary DENV infection stimulates a DENV se-
rotype–cross-neutralizing response that evolves over time into a
more monotypic response.
Temporal Analysis of Antibody Responses Following Repeat
DENV Infections
After seeing temporal changes in antibody responses following
primary infections, we measured changes in DENV-specific an-
tibodies as a function of time following repeat DENV infections.
We focused on apparent infections for which dates of actual
infection were known (Figure 2A). There was a significant
Figure 1. Antibody responses following primary dengue virus infections. A, B, and D, Follow-up sera from children with primary dengue virus (DENV)
infections were subjected to neutralization assays at dilutions of 1:40–10 240 in 4-fold increments against DENV1–4. Sigmoidal curves were generated, and
50% neutralization titers were calculated for each serotype. The neutralization seroconversion threshold was set to ≥50% neutralization at ≥1:40 serum
dilution for each DENV serotype. A, For primary apparent infections, the time that had elapsed since DENV fever onset was determined as amount of time
between date of acute fever onset and date of follow-up sample collection. The line was generated by linear regression analysis. Correlation between
neutralization breath and elapsed time was calculated by the Pearson product-moment correlation test. B, Sera were subjected to an immunoglobulin M
(IgM) enzyme-linked immunosorbent assay (ELISA) at a 1:50 dilution; IgM positivity was determined to be 5 SDs greater than the value for normal human
sera (n = 10; pooled). Groups were compared using the Fisher exact test, with outcome categories defined as “monotypic” (ie, seroconversion to 1 serotype)
and “heterotypic” (ie, seroconversion to ≥2 serotypes). C, Sera were subjected to an immunoglobulin G ELISA at a 1:100 dilution. Lines represent mean
OD405nm values. Means were found to be insignificant by the unpaired Student t test. D, Number of DENV serotypes neutralized in children with inapparent
or apparent infection. Groups were compared using the Fisher exact test, with outcome categories defined as monotypic and heterotypic as described above.
For all graphs, each dot represents mean value for an individual serum specimen tested in duplicate, unless otherwise noted.
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Figure 2. Temporal analysis of antibody responses following repeat dengue virus (DENV) infections. Paired baseline, acute phase, convalescent phase,
and follow-up sera (when available) from repeat apparent DENV infections were subjected to an immunoglobulin G (IgG) enzyme-linked immunosorbent
assay at a 1:100 dilution (A) and neutralization assays at dilutions of 1:40–10 240 in 4-fold increments against DENV1–4 (B and C). A, DENV IgG OD values
were calculated as fold change with respect to baseline OD values. Lines depict mean ODs, which were all compared by repeated measure 1-way analysis
of variance (ANOVA) with the Tukey multiple comparison post hoc test. B, Sigmoidal curves were generated, and 50% neutralization titers (NT50) were
calculated for each serotype. The graphs depict temporal sera collected from 1 child. C, The neutralization/seroconversion threshold was set to ≥50%
neutralization at a serum dilution of ≥1:40 for each DENV serotype. Lines show the mean number of DENV serotypes neutralized at each time point.
Time points were compared by 1-way ANOVA with the Tukey multiple comparison post hoc test. For all graphs, each dot represents the mean value for
an individual serum specimen tested in duplicate.
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increase in DENV IgG levels during the early convalescent
phase (approximately 2–4 weeks after infection), compared
with levels at baseline (P < .001) and during the acute phase
(P < .05). However, these elevated IgG levels decreased to prein-
fection and acute-phase levels by the end of the study year (fol-
low-up). Neutralization curves for sera obtained at different
times from individuals with apparent reinfections revealed
boosting of neutralizing antibody titer against the serotype of
previous infection (Figure 2B). At the convalescent phase,
there was a robust increase in neutralizing antibody titer against
multiple DENV serotypes. Although the overall magnitude of
the neutralizing antibody response was reduced at follow-up,
the response remained broadly cross-neutralizing (Figure 2B
and 2C). Our complete analysis of neutralization breadth in ap-
parent repeat infections revealed a significant and stable in-
crease that was maintained through the end of the study (ie,
throughout the follow-up period), compared with levels before
infection (ie, at baseline; P < .001) and during the acute phase
(P < .05; Figure 2C). Thus, for repeat infections, although the
overall quantity of DENV-specific IgG antibody increased and
then decreased back to levels before infection and during the
acute phase, the breath of neutralization was increased and
maintained over the duration of the study year.
Comparison of Antibody Responses of Repeat Inapparent
Versus Apparent DENV Infections
We then compared antibody responses in children experiencing
repeat inapparent infections to those in children with repeat ap-
parent infections. We found no difference in preexisting (ie, lev-
els measured at baseline; Figure 3A) or acquired (ie, levels
measured during follow-up; Figure 3B) total DENV-specific
IgG levels between these 2 groups. However, when we compared
Figure 3. Antibody responses of repeat inapparent and apparent dengue infections. Sera (when available) from repeat dengue virus (DENV) infections
were subjected to an immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA; A and B), neutralization tests (C and D), and an immunoglobulin
M (IgM) capture ELISA (D). A and B, Paired baseline and follow-up sera were used at a 1:100 dilution. A, For baseline sera, mean OD405nm values were
calculated (represented by lines). B, For follow-up sera, ODs are represented as fold-change over baseline ODs. A and B, Differences in mean ODs between
inapparent and apparent cases were found to be insignificant by the unpaired Student t test. C and D, Baseline sera were subjected to neutralization assays
at dilutions of 1:40–10 240 in 4-fold increments against DENV1–4. Sigmoidal curves were generated, and 50% neutralization titers were calculated for each
serotype. The neutralization/seroconversion threshold was set to ≥50% neutralization at a serum dilution of ≥1:40 for each DENV serotype. B, Baseline
sera were also subjected to IgM ELISA at a 1:50 dilution; IgM positivity was determined to be 5 SDs greater than the value for normal human sera (n = 10;
pooled). C and D, Groups were compared using the Fisher exact test, with outcome categories defined as “monotypic” (ie, seroconversion to one serotype)
and “heterotypic” (ie, seroconversion to ≥2 serotypes).
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preexisting neutralizing antibody levels, we found that children
who experienced repeat inapparent DENV infections were more
likely to have heterotypic neutralizing responses at baseline,
compared with children who experienced repeat apparent infec-
tions (P < .05; Figure 3C). To examine whether children with
repeat inapparent infections experienced very recent past
DENV infections, we tested preinfection sera for the presence
of DENV-specific IgM. We did not observe a correlation
between the presence of IgM and neutralization breadth or clin-
ical outcome (Figure 3D). In fact, 17 of 20 baseline sera (85%)
from children who had inapparent repeat infections were
DENV IgM negative, indicating that their prior DENV expo-
sures had not occurred in the past 6 months. These data indicate
that the neutralization breadth of preinfection antibodies has
significant bearing on the clinical outcome of subsequent
DENV infection. Furthermore, the difference in neutralization
capacity between the group with repeat inapparent infections
and the group with repeat apparent infections cannot simply
be explained by very recent exposure, based on the presence
of IgM.
Quantitative Analysis of Differences in Neutralizing Antibody
Responses Between Types
We conducted a direct analysis of the difference in neutraliza-
tion of DENV types to delve further into the neutralizing anti-
body responses in the cohort (Table 2). The breadth of response
was measured as the difference between the titer of the domi-
nantly neutralized DENV type, assumed to be of the previous
infecting type, and the titer of the other 3 types. Similar to
our aforementioned findings, we determined that children expe-
riencing repeat apparent DENV infections had more monotypic
baseline neutralizing antibody responses (ie, dominant respons-
es to a single DENV serotype) than those who acquired repeat
inapparent infections (P < .05). Interestingly, a significant dif-
ference in postinfection breadth was also observed between in-
apparent and apparent repeat infections: apparent infections
were observed to develop more-balanced responses following
infection, compared with inapparent infections (P < .05).
Thus, children whose repeat infections were inapparent had rel-
atively conserved patterns of neutralization at baseline and fol-
low-up, while children whose repeat infections were apparent
transitioned from mostly type-specific neutralization before in-
fection to broad neutralization after their repeat DENV expo-
sure. The degree of the neutralization breadth in this sample
was independent of the magnitude of the best-
neutralized DENV type before infection. Further, children
with inapparent repeat infections and those with apparent
repeat infections had similar maximum titers at baseline and
follow-up. Notably, after the study year, children with inapparent
repeat infections and those with apparent repeat infections had
higher titers than children with primary infections (P < .05).
DISCUSSION
In this study, we used blood samples collected from a Sri Lan-
kan pediatric dengue cohort to investigate antibody responses
in children with clinically inapparent DENV infections and
those with clinically apparent DENV infections. A strength of
our study is that infections were detected by using a neutraliza-
tion test to evaluate paired baseline and follow-up blood samples.
This approach is not feasible with most cohort studies because
of the difficulty of using the DENV neutralization test to ana-
lyze large sample panels. We overcame this hurdle by using a
96-well format, flow cytometry–based, high-throughout neu-
tralization assay [27, 28]. We screened baseline and follow-up




Repeat Infection, Median (IQR)
P ValueInapparent Apparent
Baseline NA 3.21 (2.20–4.01) 5.10 (3.53–5.66) .03a
Follow-up 3.91 (2.52–4.51)b 3.17 (1.74–4.91) 1.49 (0.90–2.82) .04a
Maximum titerc
Baseline NA 4.39 (3.55–5.40) 4.58 (3.78–5.10) .57b
Follow-up 4.39 (3.73–6.69) 6.48 (5.61–7.26) 5.87 (5.03–6.67) .02d
The breadth of response, expressed as log2[reciprocal NT50 / 10], is a measure of the average difference in titer between the DENV serotype best neutralized by a
serum specimen (the maximum titer) and the titers for each of the other 3 DENV serotypes. A value close to 0 indicates that the serum specimen neutralized all
DENV types similarly, whereas higher values indicate that the serum specimen neutralized one DENV type significantly better than it neutralized the other 3 types.
Abbreviations: IQR, interquartile range; NA, not applicable; NT50, 50% neutralization titer.
a By the Wilcoxon rank sum test, for difference between repeat inapparent and apparent infections.
b By the Wilcoxon rank sum test, for difference in breadth between primary infections and repeat infections. The difference between primary infections and repeat
inapparent infections at baseline was not significant (P = .3).
c Maximum titer for each individual, regardless of the infecting type, is shown.
d By the Kruskal–Wallis test, for difference in maximum titer between primary infections, inapparent repeat infections, and apparent repeat infections.
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samples from all enrolled children at 2 dilutions for the
presence of neutralizing antibody before selecting samples for
more-comprehensive neutralization testing (Supplementary
Materials). Our study demonstrates that, while simple to per-
form, IgG ELISA and related assays are unreliable methods
for detection of DENV infections when samples are collected
12 months apart, particularly for repeat infections. In repeat in-
fections, while total DENV-specific IgG levels initially in-
creased, over several months they declined back to baseline
levels. In contrast, neutralizing antibody breadth appeared to
be permanently changed after a repeat infection.
With respect to primary DENV infections, factors other than
preexisting immunity, such as infecting DENV strain or sero-
type and/or intrinsic host factors, must influence development
of inapparent versus apparent infection [30–33]. Here, we ex-
plored whether inapparent and apparent primary infections
stimulated different antibody responses in children and found
no differences in DENV-specific IgG or neutralization quality.
Our data also demonstrated that the duration of time following
primary DENV infections negatively correlated with the
breadth of neutralization, suggesting that neutralizing antibody
responses evolve from cross-neutralizing to serotype-specific
responses by 8–12 months after infection. Others have also
observed that primary DENV exposure results in cross-
neutralizing/protective antibodies that gradually become
monotypic as time elapses [34–36], although the mechanisms
responsible for the waning of cross-neutralization following pri-
mary DENV infections have not been defined. We observed a
strong association between the presence of DENV-specific
IgM and cross-neutralization, indicating that IgM may, in
part, be responsible for cross-neutralization. However, IgM can-
not be the only explanation because the period of transient
cross-neutralization extended to 8–12 months, which is well be-
yond the 3–6-month window after infection during which IgM
is detectable.
For repeat apparent infections, we characterized antibody
quantity and quality before, during, and after infection. Al-
though we did not observe a significant rise in levels of
DENV-specific IgG during the acute phase of infection, by 2–
4 weeks after infection most children had elevated levels of IgG,
compared with preinfection levels. Surprisingly, the elevation in
IgG levels after repeat infection was not stable; in fact, when fol-
low-up samples were collected several months after reinfection,
IgG levels had declined to preinfection and acute-phase levels.
During the acute phase, we observed boosting of neutralizing
antibody response to the previously infecting serotype in most
repeat infection cases. At 2–4 weeks after a repeat infection,
children had high levels of cross-neutralizing antibodies.
When follow-up samples were collected several months later, al-
though the overall magnitude of neutralizing antibody had de-
creased, the breath of neutralizing antibody remained greater
than in the sample obtained before repeat infection. We did
not follow these children for >12 months, but we believe that
these cross-neutralizing antibody responses are long-lived, per-
haps for a lifetime. Thus, although, the quantity of DENV-
specific IgG following a repeat DENV infection returned to
preinfection and acute-phase levels, the quality of the neutrali-
zation response was stably altered.
Many studies have focused on how antibodies may enhance
DENV infections and increase the risk of developing dengue
hemorrhagic fever [10, 12–16]. While it is well documented
that most DENV infections are clinically inapparent [3], factors
responsible for inapparent infections have not been thoroughly
investigated. Here, we observed a strong association between the
breadth of neutralization and the manifestation of symptoms,
by comparing the number of serotypes neutralized and quanti-
fying the relative breadth of neutralization before repeat infec-
tions. We found that children with repeat inapparent infections
had a greater number of broadly neutralizing preexisting DENV
antibodies than children with apparent reinfections. This is per-
haps our most interesting finding in that it demonstrates an as-
sociation between the breadth of preexisting DENV neutralizing
antibodies and the likelihood of developing an inapparent ver-
sus an apparent infection, thus suggesting an important role of
preexisting neutralizing antibodies in protection from clinical
symptom manifestation in repeat DENV infections.
There are different nonexclusive possible explanations for
this association. Recent studies based on careful analysis of se-
rial first, second, and third DENV infections in Nicaragua and
models based on large dengue data sets from Thailand indicate
that the period of cross-protection after a primary infection can
be up to 2–3 years after infection [37, 38]. Children in our study
who had secondary inapparent infections may have been more
recently exposed to their first infection, compared with children
who had secondary apparent infections. Our data showing the
absence of IgM in baseline samples from nearly all children with
repeat infections (both apparent and inapparent) demonstrates
that these repeat cases did not occur within the first 6 months of
the first infection. It remains possible that children who had sec-
ondary inapparent infections were still within the 1–3-year win-
dow of cross-protection, unlike children who had secondary
apparent infections, who were well beyond this period of
cross-protection.
Another possibility is that children experiencing repeat ap-
parent infections were exposed to secondary infections, whereas
most inapparent cases resulted from tertiary or quaternary (ie,
postsecondary) exposure. Thus, the broadly neutralizing base-
line responses may have been due to ≥2 previous DENV infec-
tions, whereas the children with monotypic responses may have
only been exposed to a single serotype. Indeed, a recent study
using cohort samples from Iquitos, Peru, demonstrated that in-
dividuals experiencing postsecondary infections were more like-
ly to develop inapparent infections, compared with people with
so-called true second infections [17]. It is worthwhile to note
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that, although it is possible that children who appeared to have
inapparent second infections were actually experiencing post-
secondary infections, the degree of neutralization breadth we
observed before infection in those cases was not significantly
different from that for children with primary infections
(P = .3; Table 2). It is likely that proximity to previous infection
and number of previous infections, together with person-to-
person variation, all influence whether someone will experience
inapparent or apparent DENV reinfection.
Our study was not designed to explore questions about the
role of antibodies in dengue hemorrhagic fever, which is typi-
cally seen in <5% of apparent dengue cases and 1% of dengue
cases overall [39]. Even with a rising incidence of severe dengue
in Sri Lanka [26], our cohort size of 799 children was too small
to obtain the number of dengue hemorrhagic fever cases re-
quired for such analysis [8].The role of antibodies in inapparent
infections is a neglected topic and increasingly relevant as
dengue vaccines enter clinical trials. Recent trial results of a
highly anticipated DENV vaccine candidate signify the impor-
tance of understanding the role that preexisting DENV neutral-
izing antibodies play in protection from subsequent dengue
disease and adverse clinical outcomes [40]. Our findings
point to an important role for heterotypic neutralizing anti-
bodies in protection from dengue disease. Further studies are
needed to better define the protective properties of these
cross-neutralizing antibodies.
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